PMID- 18218293
OWN - NLM
STAT- MEDLINE
DCOM- 20080229
LR  - 20190608
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 46
IP  - 1
DP  - 2008 Jan
TI  - Long-term remission in schizophrenia and related psychoses with long-acting 
      risperidone: results obtained in an open-label study with an observation period 
      of 18 months.
PG  - 14-22
AB  - OBJECTIVE: To monitor long-term symptomatic tolerability and remission in 
      patients with stable but suboptimally treated psychoses after switching to 
      risperidone long-acting injectable (RLAI). METHOD: This subgroup analysis of the 
      Switch to Risperidone Microspheres (StoRMi) open-label trial followed up patients 
      with psychoses who were converted to RLAI for a period of 18 months or until RLAI 
      became commercially available in their country of residence. It included patients 
      from seven European countries. Dosage adjustments were performed as clinically 
      necessary. The efficacy endpoint was achieving and maintaining remission, defined 
      as absent to mild core schizophrenia symptoms for > or = 6 months. A 
      schizophrenia assessment was also completed and patients were monitored for the 
      development of adverse events (AEs). Discontinuation rates were calculated based 
      on Kaplan-Meier estimates where patients switching to commercial RLAI were used 
      as censored observations. RESULTS: A total of 529 patients were followed for up 
      to 18 months. At 18 months, the discontinuation rate was 55.7% based on 
      Kaplan-Meier estimates. The median time to discontinuation was 15.7 months (95% 
      CI (14.0; 17.5)). RLAI was generally well tolerated with most AEs 
      mild-to-moderate in severity. 13% of patients discontinued treatment because of 
      an AE. Body weight of patients increased by a mean A+/- SD of 1.0 A+/- 6.1 kg 
      from treatment initiation to endpoint (p = 0.0001). Glucose-related AEs occurred 
      in four patients (0.8%). Among those patients not meeting severity remission 
      criteria at baseline, 44.8% were in remission at endpoint. Among those patients 
      meeting severity criteria for remission at baseline, 84.2% were in remission at 
      endpoint. A total of 93.7% of the patients who achieved or maintained remission 
      at 6 months were in remission at endpoint. CONCLUSIONS: RLAI is safe during 
      long-term treatment up to 18 months in adults requiring antipsychotics. 
      Conversion to RLAI resulted in improved symptom control. Most patients achieved 
      and maintained a sustained remission (> or = 6 months) after conversion to RLAI.
FAU - Llorca, P-M
AU  - Llorca PM
AD  - CMP B, CHU Clermont-Ferrand, Clermont-Ferrand, France.
FAU - Sacchetti, E
AU  - Sacchetti E
FAU - Lloyd, K
AU  - Lloyd K
FAU - Kissling, W
AU  - Kissling W
FAU - Medori, R
AU  - Medori R
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular
MH  - Male
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*drug therapy
MH  - Risperidone/administration & dosage/adverse effects/*therapeutic use
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
EDAT- 2008/01/26 09:00
MHDA- 2008/03/01 09:00
CRDT- 2008/01/26 09:00
PHST- 2008/01/26 09:00 [pubmed]
PHST- 2008/03/01 09:00 [medline]
PHST- 2008/01/26 09:00 [entrez]
AID - 10.5414/cpp46014 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2008 Jan;46(1):14-22. doi: 10.5414/cpp46014.